## Joshua T Schiffer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3639795/publications.pdf Version: 2024-02-01



IOSHUA T SCHIEFER

#	Article	IF	CITATIONS
1	Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet Infectious Diseases, The, 2017, 17, 1303-1316.	4.6	199
2	Viral load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading events. ELife, 2021, 10, .	2.8	142
3	Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. Science Advances, 2020, 6, .	4.7	128
4	The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality. Blood, 2017, 129, 2316-2325.	0.6	126
5	Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18973-18978.	3.3	112
6	Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet, The, 2012, 379, 641-647.	6.3	104
7	Optimizing vaccine allocation for COVID-19 vaccines shows the potential role of single-dose vaccination. Nature Communications, 2021, 12, 3449.	5.8	101
8	Frequent Release of Low Amounts of Herpes Simplex Virus from Neurons: Results of a Mathematical Model. Science Translational Medicine, 2009, 1, 7ra16.	5.8	100
9	Targeted DNA Mutagenesis for the Cure of Chronic Viral Infections. Journal of Virology, 2012, 86, 8920-8936.	1.5	100
10	A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation. Nature Communications, 2018, 9, 4811.	5.8	96
11	AAV-Mediated Delivery of Zinc Finger Nucleases Targeting Hepatitis B Virus Inhibits Active Replication. PLoS ONE, 2014, 9, e97579.	1.1	95
12	Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nature Medicine, 2013, 19, 280-288.	15.2	87
13	Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica, 2009, 94, 1101-1108.	1.7	86
14	Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood, 2021, 138, 34-43.	0.6	71
15	COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. Scientific Reports, 2021, 11, 15531.	1.6	70
16	Longitudinal study reveals HIV-1–infected CD4+ T cell dynamics during long-term antiretroviral therapy. Journal of Clinical Investigation, 2020, 130, 3543-3559.	3.9	69
17	Timing of Antiretroviral Therapy Initiation in Tuberculosis Patients With AIDS. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 229-234.	0.9	67
18	Herpes simplex virus-2 transmission probability estimates based on quantity of viral shedding. Journal of the Royal Society Interface, 2014, 11, 20140160.	1.5	67

#	Article	IF	CITATIONS
19	HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa. Epidemics, 2010, 2, 173-182.	1.5	61
20	Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. ELife, 2013, 2, e00288.	2.8	59
21	Kinetics of Double-Stranded DNA Viremia After Allogeneic Hematopoietic Cell Transplantation. Clinical Infectious Diseases, 2018, 66, 368-375.	2.9	56
22	Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. EClinicalMedicine, 2021, 33, 100773.	3.2	55
23	New concepts in understanding genital herpes. Current Infectious Disease Reports, 2009, 11, 457-464.	1.3	54
24	The Kinetics of Mucosal Herpes Simplex Virus–2 Infection in Humans: Evidence for Rapid Viral-Host Interactions. Journal of Infectious Diseases, 2011, 204, 554-561.	1.9	54
25	Plasma and Cerebrospinal Fluid Herpes Simplex Virus Levels at Diagnosis and Outcome of Neonatal Infection. Journal of Pediatrics, 2015, 166, 827-833.	0.9	47
26	Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. MBio, 2021, 12, e0334721.	1.8	45
27	Complementing 16S rRNA Gene Amplicon Sequencing with Total Bacterial Load To Infer Absolute Species Concentrations in the Vaginal Microbiome. MSystems, 2020, 5, .	1.7	44
28	A highly multiplexed droplet digital PCR assay to measure the intact HIV-1 proviral reservoir. Cell Reports Medicine, 2021, 2, 100243.	3.3	44
29	Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Research, 2016, 126, 90-98.	1.9	43
30	Rapid Viral Expansion and Short Drug Half-Life Explain the Incomplete Effectiveness of Current Herpes Simplex Virus 2-Directed Antiviral Agents. Antimicrobial Agents and Chemotherapy, 2013, 57, 5820-5829.	1.4	42
31	Dynamics of HIV DNA reservoir seeding in a cohort of superinfected Kenyan women. PLoS Pathogens, 2020, 16, e1008286.	2.1	41
32	Tissue-resident T cell–derived cytokines eliminate herpes simplex virus-2–infected cells. Journal of Clinical Investigation, 2020, 130, 2903-2919.	3.9	40
33	Predictors of Hepatitis B Cure Using Gene Therapy to Deliver DNA Cleavage Enzymes: A Mathematical Modeling Approach. PLoS Computational Biology, 2013, 9, e1003131.	1.5	36
34	Population Level Impact of an Imperfect Prophylactic Vaccine for Herpes Simplex Virus-2. Sexually Transmitted Diseases, 2010, 37, 290-297.	0.8	36
35	Anti-proliferative therapy for HIV cure: a compound interest approach. Scientific Reports, 2017, 7, 4011.	1.6	35
36	CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. Journal of Clinical Investigation, 2021, 131, .	3.9	35

3

#	Article	IF	CITATIONS
37	Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development. Vaccine, 2019, 37, 7363-7371.	1.7	31
38	Decreased CD4+ lymphocytes and innate immune responses in adults with previous extrapulmonary tuberculosis. Journal of Allergy and Clinical Immunology, 2006, 117, 916-923.	1.5	30
39	Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. Journal of Antimicrobial Chemotherapy, 2011, 66, 2593-2600.	1.3	30
40	Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus–Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2016, 22, 149-156.	2.0	30
41	Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4 <sup>+</sup> T cell activation and HIV-1 latency reversal. Science Advances, 2019, 5, eaav6322.	4.7	30
42	CD4 T-Cell Memory Responses to Viral Infections of Humans Show Pronounced Immunodominance Independent of Duration or Viral Persistence. Journal of Virology, 2013, 87, 2617-2627.	1.5	29
43	Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes. Science Translational Medicine, 2016, 8, 324ra15.	5.8	29
44	Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir. BMC Biology, 2018, 16, 75.	1.7	29
45	Widespread testing, case isolation and contact tracing may allow safe school reopening with continued moderate physical distancing: A modeling analysis of King County, WA data. Infectious Disease Modelling, 2021, 6, 24-35.	1.2	29
46	Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants. Pediatric Infectious Disease Journal, 2018, 37, 627-631.	1.1	28
47	A regulatory T cell signature distinguishes the immune landscape of COVID-19 patients from those with other respiratory infections. Science Advances, 2021, 7, eabj0274.	4.7	28
48	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. PLoS Pathogens, 2021, 17, e1009214.	2.1	25
49	Mucosal HSV-2 Specific CD8+ T-Cells Represent Containment of Prior Viral Shedding Rather than a Correlate of Future Protection. Frontiers in Immunology, 2013, 4, 209.	2.2	24
50	The Majority of CD4 + T-Cell Depletion during Acute Simian-Human Immunodeficiency Virus SHIV89.6P Infection Occurs in Uninfected Cells. Journal of Virology, 2014, 88, 3202-3212.	1.5	24
51	Dynamics of Persistent Oral Cytomegalovirus Shedding During Primary Infection in Ugandan Infants. Journal of Infectious Diseases, 2016, 214, 1735-1743.	1.9	24
52	Peripheral Blood CD4 T-Cell and Plasmacytoid Dendritic Cell (pDC) Reactivity to Herpes Simplex Virus 2 and pDC Number Do Not Correlate with the Clinical or Virologic Severity of Recurrent Genital Herpes. Journal of Virology, 2012, 86, 9952-9963.	1.5	23
53	Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study. PLoS Medicine, 2017, 14, e1002475.	3.9	22
54	Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa. PLoS ONE, 2016, 11, e0155124.	1.1	22

#	Article	IF	CITATIONS
55	Herpes simplex virusâ€⊋ dynamics as a probe to measure the extremely rapid and spatially localized tissueâ€resident Tâ€cell response. Immunological Reviews, 2018, 285, 113-133.	2.8	21
56	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. PLoS Computational Biology, 2020, 16, e1007626.	1.5	20
57	Estimating the Risk of Human Herpesvirus 6 and Cytomegalovirus Transmission to Ugandan Infants from Viral Shedding in Saliva by Household Contacts. Viruses, 2020, 12, 171.	1.5	20
58	A Fixed Spatial Structure of CD8+ T Cells in Tissue during Chronic HSV-2 Infection. Journal of Immunology, 2018, 201, 1522-1535.	0.4	19
59	Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children. Scientific Reports, 2017, 7, 13105.	1.6	18
60	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. Human Vaccines and Immunotherapeutics, 2018, 14, 2116-2127.	1.4	17
61	Review of mathematical models of HSV-2 vaccination: Implications for vaccine development. Vaccine, 2019, 37, 7396-7407.	1.7	17
62	Slight reduction in SARS-CoV-2 exposure viral load due to masking results in a significant reduction in transmission with widespread implementation. Scientific Reports, 2021, 11, 11838.	1.6	17
63	An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infectious Diseases, 2020, 7, ofaa232.	0.4	16
64	HIV reservoir quantification using cross-subtype multiplex ddPCR. IScience, 2022, 25, 103615.	1.9	16
65	Multi-scale modelling reveals that early super-spreader events are a likely contributor to novel variant predominance. Journal of the Royal Society Interface, 2022, 19, 20210811.	1.5	16
66	Autologous Stem Cell Transplantation Disrupts Adaptive Immune Responses during Rebound Simian/Human Immunodeficiency Virus Viremia. Journal of Virology, 2017, 91, .	1.5	15
67	Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. Microorganisms, 2021, 9, 566.	1.6	13
68	Reliability of Self-Sampling for Accurate Assessment of Respiratory Virus Viral and Immunologic Kinetics. Journal of Infectious Diseases, 2022, 226, 278-286.	1.9	10
69	Cervicovaginal Tissue Residence Confers a Distinct Differentiation Program upon Memory CD8 T Cells. Journal of Immunology, 2021, 206, 2937-2948.	0.4	10
70	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. Viruses, 2021, 13, 1921.	1.5	10
71	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020—March 2021) Using a Statistical Learning Strategy. Viruses, 2022, 14, 9.	1.5	10
72	Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation. ELife, 2021, 10, .	2.8	9

#	Article	lF	CITATIONS
73	Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads. PLoS Computational Biology, 2021, 17, e1009072.	1.5	9
74	Timing HIV infection with a simple and accurate population viral dynamics model. Journal of the Royal Society Interface, 2021, 18, 20210314.	1.5	8
75	Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention. PLoS Computational Biology, 2022, 18, e1010003.	1.5	8
76	Herpes Simplex Virus-2 Genital Tract Shedding Is Not Predictable over Months or Years in Infected Persons. PLoS Computational Biology, 2014, 10, e1003922.	1.5	7
77	Myeloablation-associated deletion of ORF4 in a human coronavirus 229E infection. Npj Genomic Medicine, 2017, 2, 30.	1.7	7
78	Rapid vaccination and partial lockdown minimize 4th waves from emerging highly contagious SARS-CoV-2 variants. Med, 2021, 2, 573-574.	2.2	7
79	Modeling explains prolonged SARS-CoV-2 nasal shedding relative to lung shedding in remdesivir-treated rhesus macaques. IScience, 2022, 25, 104448.	1.9	7
80	A curative regimen would decrease HIV prevalence but not HIV incidence unless targeted to an ART-naÃ <sup>-</sup> ve population. Scientific Reports, 2016, 6, 22183.	1.6	6
81	Quantifying the Impact of Lifting Community Nonpharmaceutical Interventions for COVID-19 During Vaccination Rollout in the United States. Open Forum Infectious Diseases, 2021, 8, ofab341.	0.4	6
82	With Jaundiced Eyes. American Journal of Medicine, 2009, 122, 21-23.	0.6	5
83	Pharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases. Journal of Antimicrobial Chemotherapy, 2016, 71, 2089-2099.	1.3	5
84	Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans. Viruses, 2021, 13, 516.	1.5	5
85	Cases from the Osler Medical Service at Johns Hopkins University. American Journal of Medicine, 2003, 115, 404-406.	0.6	4
86	A siege of hepatitis: Fighting a defiant virus. Nature Medicine, 2011, 17, 253-254.	15.2	4
87	Viral Kinetic Correlates of Cytomegalovirus Disease and Death after Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2018, 24, S20.	2.0	4
88	To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia. Haematologica, 2018, 103, 1756-1757.	1.7	4
89	Mathematical Modeling of Within-Host, Untreated, Cytomegalovirus Infection Dynamics after Allogeneic Transplantation. Viruses, 2021, 13, 2292.	1.5	4
90	Feverish, Jaundiced. American Journal of Medicine, 2009, 122, 129-131.	0.6	3

6

#	Article	IF	CITATIONS
91	Evolution during primary HIV infection does not require adaptive immune selection. Proceedings of the United States of America, 2022, 119, .	3.3	3
92	Outcomes of Hematopoietic Cell Transplantation in Patients with Mixed Response to Pretransplantation Treatment of Confirmed or Suspected Invasive Fungal Infection. Transplantation and Cellular Therapy, 2021, 27, 684.e1-684.e9.	0.6	2
93	Improving vaccination coverage and offering vaccine to all school-age children allowed uninterrupted in-person schooling in King County, WA: Modeling analysis. Mathematical Biosciences and Engineering, 2022, 19, 5699-5716.	1.0	2
94	P3.119â€The effect of HSV-2 infection on subsequent hiv acquisition: an updated systematic review and meta-analysis. , 2017, , .		1
95	Model-based estimation of superinfection prevalence from limited datasets. Journal of the Royal Society Interface, 2018, 15, 20170968.	1.5	1
96	Reply to Giménez et al. Clinical Infectious Diseases, 2018, 67, 807-808.	2.9	1
97	CMV Viral Load Kinetics as Surrogate Endpoints for Antiviral Prophylaxis Trials. Biology of Blood and Marrow Transplantation, 2020, 26, S327-S328.	2.0	1
98	Detection of Multiple Double-Stranded DNA Viruses after Cord Blood Transplantation Is Frequent and Persistent. Blood, 2015, 126, 3104-3104.	0.6	1
99	Estimation of the in vivo neutralization potency of eCD4lg and conditions for AAV-mediated production for SHIV long-term remission. Science Advances, 2022, 8, eabj5666.	4.7	1
100	Correlates of protection via modeling. Nature Computational Science, 2022, 2, 140-141.	3.8	1
101	Multisystem Mystery. American Journal of Medicine, 2008, 121, 387-389.	0.6	0
102	Kinetic Features of Double Stranded DNA Virus Detection after Allogeneic Hematopoietic Cell Transplantation. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
103	Detection of Multiple Double-Stranded DNA Viruses after Allogeneic HCT Is Frequent, Persistent, and Associated with a Stepwise Increase in Mortality. Biology of Blood and Marrow Transplantation, 2016, 22, S166-S167.	2.0	0
104	CMV, BKV, HHV-6B, AdV, and EBV Kinetics after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S165-S166.	2.0	0
105	In the Eye of the Beholder: A Conjunctival Lesion in a Woman With Acute Myelogenous Leukemia. Clinical Infectious Diseases, 2019, 68, 525-529.	2.9	0
106	Determination of Optimal Viral Kinetic Markers for Predicting Antiviral Treatment Effect for the Prevention of Cytomegalovirus (CMV) Disease after Hematopoietic Cell Transplant (HCT) Using Machine Learning and a Novel Non-Parametric Estimation Method. Biology of Blood and Marrow Transplantation, 2019, 25, S345.	2.0	0
107	Title is missing!. , 2020, 16, e1007626.		0

108 Title is missing!. , 2020, 16, e1007626.

#	Article	IF	CITATIONS
109	Title is missing!. , 2020, 16, e1007626.		0
110	Title is missing!. , 2020, 16, e1007626.		0

Title is missing!. , 2020, 16, e1007626. 110